statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on...

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Chemomab Therapeutics awarded European patent for CM-101

European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis Further Extends Protections Afforded by CM-101...

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. (NASDAQ:CMMB  Get Free Report) saw a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 244,300...

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 549.7% in February

Chemomab Therapeutics (NASDAQ:CMMB  Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts consensus...

Chemomab Therapeutics (NASDAQ:CMMB) Issues  Earnings Results

Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.01...

Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.01

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference PR Newswire TEL AVIV, Israel, March 5, 2024 TEL...

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Chemomab Therapeutics awarded new patents for CM-101 in Brazil and Israel

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases Chemomab Awarded New Patents for CM-101, Its First-in Class...

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results...

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Volume	289.00
52-Wk High	$1.89
52-Wk Low	$0.42

CMMB Chemomab Therapeutics Ltd - ADR

About

Feed

News

Fundamentals